Elevated D-dimer levels are a marker of both thrombin formation and fibrinolysis. Currently D-dimer measurement is routinely used for ruling out venous thromboembolism and diagnosis/monitoring of disseminated intravascular coagulation. Recent emerging data suggest that D-dimer may become an important biomarker in ischemic stroke as well as in cardiovascular diseases.
Aims
To outline the clinical utility of D-dimer in work-up and management of ischemic stroke.
Summary
D-dimer measurement is most useful in stroke with active cancer as it can confirm etiologic diagnosis, predict recurrent stroke risk, and aid treatment decision in cancer-associated stroke. In cryptogenic stroke, high D-dimer levels can also provide clues for the cause of stroke as occult cancer and undetected cardiac embolic source as occult atrial fibrillation and may be helpful in treatment decision making of secondary stroke prevention. Serial D-dimer measurements should be further studied to monitor antithrombotic therapy effectiveness in both cardiogenic and cryptogenic etiologies.
Conclusion
Accumulating data suggests the utility of D-dimer test in the management of ischemic stroke, although the evidence is still limited. Future studies would clarify the role of D-dimer measurement in ischemic stroke.
KonstantinidesSVTorbickiAAgnelliG, et al.2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J2014; 35: 3033–3069. 3069a–3069k.
3.
GeersingGJZuithoffNPKearonC, et al.Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ2014; 348: g1340.
4.
SoomroAYGuerchicoffANicholsDJ, et al.The current role and future prospects of D-dimer biomarker. Eur Heart J Cardiovasc Pharmacother2016; 2: 175–184.
5.
HaapaniemiETatlisumakT. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol Scand2009; 119: 141–150.
6.
TakanoKYamaguchiTUchidaK. Markers of a hypercoagulable state following acute ischemic stroke. Stroke1992; 23: 194–198.
7.
AgenoWFinazziSSteidlL, et al.Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med2002; 162: 2589–2593.
8.
MontanerJPerea-GainzaMDelgadoP, et al.Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke2008; 39: 2280–2287.
9.
Alvarez-PerezFJCastelo-BrancoMAlvarez-SabinJ. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J Neurol Neurosurg Psychiatry2011; 82: 986–992.
10.
HiranoKTakashimaSDouguN, et al.Study of hemostatic biomarkers in acute ischemic stroke by clinical subtype. J Stroke Cerebrovasc Dis2012; 21: 404–410.
11.
IseneggerJMeierNLammleB, et al.D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis2010; 29: 82–86.
12.
ZiWJShuaiJ. Plasma D-dimer levels are associated with stroke subtypes and infarction volume in patients with acute ischemic stroke. PLoS One2014; 9: e86465.
13.
LiuLBLiMZhuoWY, et al.The role of hs-CRP, D-dimer and fibrinogen in differentiating etiological subtypes of ischemic stroke. PLoS One2015; 10: e0118301.
14.
WisemanSMarlboroughFDoubalF, et al.Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis2014; 37: 64–75.
15.
ZeccaBMandelliCMainoA, et al.A bioclinical pattern for the early diagnosis of cardioembolic stroke. Emerg Med Int2014; 2014: 242171.
16.
TomichCLiegeyJSSagnierS, et al.Contribution of routine cardiac biological markers to the etiological workup of ischemic stroke. Am J Emerg Med2019; 37: 194–198.
17.
BrounsRVan Den BosscheJDe SurgelooseD, et al.Clinical and biochemical diagnosis of small-vessel disease in acute ischemic stroke. J Neurol Sci2009; 285: 185–190.
18.
ChristerssonCWallentinLAnderssonU, et al.D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial. J Thromb Haemost2014; 12: 1401–1412.
19.
SiegbahnAOldgrenJAnderssonU, et al.D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb Haemost2016; 115: 921–930.
20.
HabaraSDoteKKatoM, et al.Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J2007; 28: 2217–2222.
21.
WanHWuSYangY, et al.Plasma fibrin D-dimer and the risk of left atrial thrombus: a systematic review and meta-analysis. PLoS One2017; 12: e0172272.
22.
KimTWSongIUChungSW, et al.Serum D-dimer levels are proportionally associated with left atrial enlargement in patients with an acute ischemic stroke due to non-valvular atrial fibrillation. Intern Med2016; 55: 1447–1452.
23.
HartRGDienerH-CCouttsSB, et al.Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol2014; 13: 429–438.
24.
TacconeFSJeangetteSMBlecicSA. First-ever stroke as initial presentation. of systemic cancer. J Stroke Cerebrovasc Dis2008; 17: 169–174.
25.
CochoDGendreJBoltesA, et al.Predictors of occult cancer in acute ischemic stroke patients. J Stroke Cerebrovasc Dis2015; 24: 1324–1328.
26.
UemuraJKimuraKSibazakiK, et al.Acute stroke patients have occult malignancy more often than expected. Eur Neurol2010; 64: 140–144.
27.
GonYSakaguchiMTakasugiJ, et al.Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke. Eur J Neurol2017; 24: 503–508.
28.
KimSJParkJHLeeMJ, et al.Clues to occult cancer in patients with ischemic stroke. PLoS One2012; 7: e44959.
29.
SpritzerCEArataMAFreedKS. Isolated pelvic deep venous thrombosis: relative frequency as detected with MR imaging. Radiology2001; 219: 521–525.
30.
OsgoodMBudmanECarandangR, et al.Prevalence of pelvic vein pathology in patients with cryptogenic stroke and patent foramen ovale undergoing MRV pelvis. Cerebrovasc Dis2015; 39: 216–223.
31.
EllisDRangarajuSDuncanA, et al.Coagulation markers and echocardiography predict atrial fibrillation, malignancy or recurrent stroke after cryptogenic stroke. Medicine2018; 97: e13830.
32.
LiuLBGuoYDXuAD, et al.Diagnostic value of STAF score in combination with D-dimer in cardioembolism. PLoS One2018; 13: e0204838.
33.
Di NapoliMPapaF. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke2002; 33: 1763–1771.
34.
SquizzatoAAgenoWFinazziS, et al.D-dimer is not a long-term prognostic marker following acute cerebral ischemia. Blood Coagul Fibrinolysis2006; 17: 303–306.
35.
GonYSakaguchiMOkazakiS, et al.Prevalence of positive diffusion-weighted imaging findings and ischemic stroke recurrence in transient ischemic attack. J Stroke Cerebrovasc Dis2015; 24: 1000–1007.
36.
KimYDSongDNamHS, et al.D-dimer for prediction of long-term outcome in cryptogenic stroke patients with patent foramen ovale. Thromb Haemost2015; 114: 614–622.
37.
NezuTKitanoTKuboS, et al.Impact of D-dimer levels for short-term or long-term outcomes in cryptogenic stroke patients. J Neurol2018; 265: 628–636.
38.
NaviBBIadecolaC. Ischemic stroke in cancer patients: a review of an underappreciated pathology. Ann Neurol2018; 83: 873–883.
39.
BangOYSeokJMKimSG, et al.Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes. J Clin Neurol2011; 7: 53–59.
40.
KimKLeeJH. Risk factors and biomarkers of ischemic stroke in cancer patients. J Stroke2014; 16: 91–96.
41.
LeeEJNahHWKwonJY, et al.Ischemic stroke in patients with cancer: is it different from usual strokes?. Int J Stroke2014; 9: 406–412.
42.
SchwarzbachCJSchaeferAEbertA, et al.Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. Stroke2012; 43: 3029–3034.
43.
GuoYJChangMHChenPL, et al.Predictive value of plasma D-dimer levels for cancer-related stroke: a 3-year retrospective study. J Stroke Cerebrovasc Dis2014; 23: e249–254.
44.
KimSGHongJMKimHY, et al.Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea. Stroke2010; 41: 798–801.
45.
GonYOkazakiSTerasakiY, et al.Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol2016; 3: 280–287.
46.
RyuJABangOYLeeGH. D-dimer levels and cerebral infarction in critically ill cancer patients. BMC Cancer2017; 17: 591.
47.
ItoSUedaAMurateK, et al.Differentiation of cancer from atrial fibrillation in patients with acute multifocal stroke. J Neurol Sci2016; 368: 344–348.
48.
LeeMJChungJWAhnMJ, et al.Hypercoagulability and mortality of patients with stroke and active cancer: the OASIS-CANCER Study. J Stroke2017; 19: 77–87.
49.
FujinamiJOharaTKitani-MoriiF, et al.Cancer-associated hypercoagulation increases the risk of early recurrent stroke in patients with active cancer. Cerebrovasc Dis2018; 46: 46–51.
50.
NamKWKimCKKimTJ, et al.D-dimer as a predictor of early neurologic deterioration in cryptogenic stroke with active cancer. Eur J Neurol2017; 24: 205–211.
51.
LeeAYLevineMNBakerRI, et al.Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med2003; 349: 146–153.
52.
LymanGHBohlkeKKhoranaAA, et al.Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. J Clin Oncol2015; 33: 654–656.
GeddingsJEMackmanN. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood2013; 122: 1873–1880.
55.
ChungJWChoYHAhnMJ, et al.Association of cancer cell type and extracellular vesicles with coagulopathy in patients with lung cancer and stroke. Stroke2018; 49: 1282–1285.
56.
JangHLeeJJLeeMJ, et al.Comparison of enoxaparin and warfarin for secondary prevention of cancer-associated stroke. J Oncol2015; 2015: 502089.
57.
KawanoHHondaYAmanoT, et al.Subcutaneous heparin therapy for patients with cancer-associated stroke. Stroke Cerebrovasc Dis2019; 28: 399–404.
58.
SeokJMKimSGKimJW, et al.Coagulopathy and embolic signal in cancer patients with ischemic stroke. Ann Neurol2010; 68: 213–219.
59.
AshaSEMiersJW. A systematic review and meta-analysis of D-dimer as a rule-out test for suspected acute aortic dissection. Ann Emerg Med2015; 66: 368–378.
60.
RogersAMHermannLKBooherAM, et al.Sensitivity of the aortic dissection detection risk score, a novel guideline-based tool for identification of acute aortic dissection at initial presentation: results from the international registry of acute aortic dissection. Circulation2011; 123: 2213–2218.
61.
NazerianPMuellerCSoeiroAM, et al.Diagnostic accuracy of the aortic dissection detection risk score plus D-Dimer for acute aortic syndromes: the ADvISED Prospective Multicenter Study. Circulation2018; 137: 250–258.
62.
SakamotoYKogaMOharaT, et al.Frequency and detection of Stanford Type A aortic dissection in hyperacute stroke management. Cerebrovasc Dis2016; 42: 110–116.
63.
GaulCDietrichWFriedrichI, et al.Neurological symptoms in type A aortic dissections. Stroke2007; 38: 292–297.
64.
OharaTKogaMTokudaN, et al.Rapid identification of Type A aortic dissection as a cause of acute ischemic stroke. J Stroke Cerebrovasc Dis2016; 25: 1901–1906.
65.
KogaMIguchiYOharaT, et al.Acute ischemic stroke as a complication of Stanford type A acute aortic dissection: a review and proposed clinical recommendations for urgent diagnosis. Gen Thorac Cardiovasc Surg2018; 66: 439–445.
66.
TokudaNKogaMOharaT, et al.Urgent detection of acute Type A aortic dissection in hyperacute ischemic stroke or transient ischemic attack. J Stroke Cerebrovasc Dis2018; 27: 2112–2117.
67.
HuangCHHuangHCLinKH, et al.Identification of painless aortic dissection before thrombolytic treatment for acute ischemic stroke. Am J Emerg Med2013; 31: 762 e765–766.
68.
YeoLLLHolminSAnderssonT, et al.Nongated cardiac computed tomographic angiograms for detection of embolic sources in acute ischemic stroke. Stroke2017; 48: 1256–1261.
69.
GiannitsisEMairJChristerssonC, et al.How to use D-dimer in acute cardiovascular care. Eur Heart J Acute Cardiovasc Care2017; 6: 69–80.
70.
LinkinsLATakach LapnerS. Review of D-dimer testing: good, bad, and ugly. Int J Lab Hematol2017; 39(Suppl 1): 98–103.
71.
SchutteTThijsASmuldersYM. Never ignore extremely elevated D-dimer levels: they are specific for serious illness. Neth J Med2016; 74: 443–448.
72.
FassbenderKDempfleCEMielkeO, et al.Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke1999; 30: 2101–2104.
73.
HuangXMoretonFCKalladkaD, et al.Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke. Stroke2015; 46: 3543–3546.
74.
SunXBerthillerJDerexL, et al.Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome. J Neurol Sci2015; 349: 77–83.
75.
HartRGSharmaMMundlH, et al.Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med2018; 378: 2191–2201.
76.
DienerHCSaccoRLEastonJD, et al.Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Eng J Med2019; 380: 1906–1917.
77.
KamelHMerklerAEIadecolaC, et al.Tailoring the approach to embolic stroke of undetermined source: a review. JAMA Neurol2019; 76: 855–861.
78.
LipGYLoweGDRumleyA, et al.Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J1995; 73: 527–533.
79.
NakataniYMizumakiKNishidaK, et al.Anticoagulation control quality affects the D-dimer levels of atrial fibrillation patients. Circ J2012; 76: 317–321.
80.
MaheIBergmannJFChassanyO, et al.A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation. Thromb Res2012; 129: 693–699.
81.
ZhangLZhengXLongY, et al.D-dimer to guide the intensity of anticoagulation in Chinese patients after mechanical heart valve replacement: a randomized controlled trial. J Thromb Haemost2017; 15: 1934–1941.
82.
MatsumotoMSakaguchiMOkazakiS, et al.Relationship between plasma D-dimer level and cerebral infarction volume in patients with nonvalvular atrial fibrillation. Cerebrovasc Dis2013; 35: 64–72.
83.
KimTKooJSongI-U, et al.Cardiovascular biomarkers during acute periods of ischemic stroke due to non-valvular atrial fibrillation. J Neurocrit Care2018; 11: 23–31.
84.
LiWJShaMMaW, et al.Efficacy evaluation of D-dimer and modified criteria in overt and nonovert disseminated intravascular coagulation diagnosis. Int J Lab Hematol2016; 38: 151–159.
85.
LiWHuangBTianL, et al.Admission D-dimer testing for differentiating acute aortic dissection from other causes of acute chest pain. Arch Med Sci2017; 13: 591–596.
86.
BjoriEJohnsenHSHansenJB, et al.D-dimer at venous thrombosis diagnosis is associated with risk of recurrence. J Thromb Haemost2017; 15: 917–924.
87.
LippiGBonfantiLSaccentiC, et al.Causes of elevated D-dimer in patients admitted to a large urban emergency department. Eur J Intern Med2014; 25: 45–48.
88.
WangMLuSLiS, et al.Reference intervals of D-dimer during the pregnancy and puerperium period on the STA-R evolution coagulation analyzer. Clin Chim Acta2013; 425: 176–180.
